Petros Pharmaceuticals Inc (PTPI) - Total Liabilities
Based on the latest financial reports, Petros Pharmaceuticals Inc (PTPI) has total liabilities worth $27.19 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PTPI cash flow metrics to assess how effectively this company generates cash.
Petros Pharmaceuticals Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Petros Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Petros Pharmaceuticals Inc shareholders equity for net asset value and shareholders' equity analysis.
Petros Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Petros Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gresham House Renewable Energy VCT 1 plc
LSE:GV1O
|
UK | GBX4.26 Million |
|
STORA ENSO OYJ R (RE-REG)
F:ENUN
|
Germany | €8.41 Billion |
|
ECR Minerals plc
LSE:ECR
|
UK | GBX81.15K |
|
Stora Enso Oyj ser. R
ST:STE-R
|
Sweden | Skr9.40 Billion |
|
Cloudbreak Discovery PLC
LSE:CDL
|
UK | GBX614.34K |
|
ADVANCED INF SERV(ADVANC)
STU:NVAA
|
Belgium | €312.99 Billion |
|
Stora Enso Oyj ser. A
ST:STE-A
|
Sweden | Skr8.41 Billion |
|
Global Lights Acquisition Corp Unit
NASDAQ:GLACU
|
USA | $2.99 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Petros Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Petros Pharmaceuticals Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Petros Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Petros Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Petros Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.10 Million | -15.07% |
| 2023-12-31 | $21.32 Million | +35.61% |
| 2022-12-31 | $15.72 Million | -50.64% |
| 2021-12-31 | $31.85 Million | -39.21% |
| 2020-12-31 | $52.38 Million | +4.05% |
| 2019-12-31 | $50.35 Million | -26.57% |
| 2018-12-31 | $68.57 Million | -- |
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.